Unicycive Therapeutics’ (UNCY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a research note published on Wednesday morning,Benzinga reports. They currently have a $4.00 price objective on the stock.

Separately, Benchmark reiterated a “speculative buy” rating and issued a $3.00 price objective on shares of Unicycive Therapeutics in a research report on Friday, November 22nd. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $5.50.

Unicycive Therapeutics Price Performance

Shares of NASDAQ UNCY opened at $0.61 on Wednesday. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.82. The firm has a market capitalization of $63.71 million, a PE ratio of -0.63 and a beta of 2.30. The business’s fifty day moving average price is $0.69 and its two-hundred day moving average price is $0.51.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in Unicycive Therapeutics in the third quarter worth about $29,000. Virtu Financial LLC raised its position in shares of Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock worth $30,000 after buying an additional 62,881 shares in the last quarter. Bleakley Financial Group LLC acquired a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth approximately $33,000. Acuta Capital Partners LLC bought a new position in shares of Unicycive Therapeutics in the third quarter valued at approximately $807,000. Finally, Walleye Capital LLC bought a new stake in Unicycive Therapeutics during the third quarter worth approximately $2,040,000. Institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.